13F filer · CIK 2102314
Jones Hill Capital LP
NEW YORK, NY · filing since Q1 2026 · last filing Aug 13, 2026
Reported value
$470.4M
+$3.9M vs prior
Positions
29
New / sold out
15 / 12
Added / reduced
5 / 9
Turnover
58.9%
buys $275.8M · sells $311.6M
Top-10 weight
68.8%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | GILEAD SCIENCES INC | +343,043 | – | +$43.3M |
| New | ARCUTIS BIOTHERAPEUTICS INC | +1,089,701 | – | +$28.6M |
| New | MADRIGAL PHARMACEUTICALS INC | +52,545 | – | +$28.2M |
| Added | RELMADA THERAPEUTICS INC | +3,312,323 | +966.4% | +$22.9M |
| New | XENON PHARMACEUTICALS INC | +367,900 | – | +$22.2M |
| Added | TREVI THERAPEUTICS INC | +969,037 | +261.8% | +$18.1M |
| Added | PHARVARIS N V | +510,865 | +305.9% | +$17.7M |
| New | IMMUNOCORE HLDGS PLC | +512,856 | – | +$16.3M |
| New | INSMED INC | +122,375 | – | +$13.0M |
| Added | BIOMARIN PHARMACEUTICAL INC | +163,200 | +12.9% | +$9.3M |
10 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Reduced | VERTEX PHARMACEUTICALS INC | -97,480 | -89.8% | $-48.4M |
| Sold out | VAXCYTE INC | -644,831 | -100.0% | $-37.5M |
| Reduced | ENLIVEN THERAPEUTICS INC | -543,190 | -91.6% | $-27.6M |
| Sold out | TERNS PHARMACEUTICALS INC | -521,237 | -100.0% | $-27.5M |
| Reduced | NUVALENT INC | -202,388 | -67.3% | $-25.0M |
| Sold out | ULTRAGENYX PHARMACEUTICAL IN | -1,165,557 | -100.0% | $-24.4M |
| Sold out | ARGENX SE | -25,995 | -100.0% | $-19.0M |
| Sold out | FULCRUM THERAPEUTICS INC | -1,771,926 | -100.0% | $-13.6M |
| Reduced | AMYLYX PHARMACEUTICALS INC | -704,736 | -44.1% | $-12.7M |
| Reduced | CAPRICOR THERAPEUTICS INC | -488,456 | -53.7% | $-11.8M |
11 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | BIOMARIN PHARMACEUTICAL INCCOM | 1,431,590 | $81.9M | 17.42% |
| 2 | GILEAD SCIENCES INCCOM | 343,043 | $43.3M | 9.21% |
| 3 | ARCUTIS BIOTHERAPEUTICS INCCOM | 1,089,701 | $28.6M | 6.07% |
| 4 | MADRIGAL PHARMACEUTICALS INCCOM | 52,545 | $28.2M | 6.00% |
| 5 | BICARA THERAPEUTICS INCCOM | 892,621 | $26.5M | 5.63% |
| 6 | RELMADA THERAPEUTICS INCCOM | 3,655,075 | $25.3M | 5.38% |
| 7 | TREVI THERAPEUTICS INCCOM | 1,339,212 | $25.0M | 5.31% |
| 8 | PHARVARIS N VCOM | 677,879 | $23.4M | 4.98% |
| 9 | XENON PHARMACEUTICALS INCCOM | 367,900 | $22.2M | 4.72% |
| 10 | ANI PHARMACEUTICALS INCCOM | 233,808 | $19.4M | 4.11% |
19 more rows. Subscribe for $29/month to see every row, download the data and use the API.